|
Indications and Dosage
Oral
Menopausal hormone replacement therapy, Prophylaxis of osteoporosis Adult: 1.4-2.8 mg daily in a cyclical or continuous regimen, usually given with estradiol and estriol. Cyclical progestogen should be given for 12-14 days of each cycle in women with intact uterus.
|
|
Contraindications
Hypersensitivity; undiagnosed vaginal bleeding; thrombophlebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumor; porphyria; pregnancy.
|
|
Special Precautions
Conditions exacerbated by fluid retention; hypercalcaemia, CV and gallbladder disease; lipid effects; familial defects of lipoprotein metabolism. Children (premature closure of epiphyses). May increase BP, risk of venous thromboembolism, risk of breast cancer, size of preexisting uterine leiomyomata and risk of benign hepatic adenoma. Lactation. Vaginal tablet: Severe atrophic vaginal mucosa or following gynaecological surgery.
|
|
Adverse Reactions
GI disturbances, genitourinary changes, haematologic disorders, CV and CNS effects, endocrine and metabolic disorders, cholestatic jaundice, local skin reactions, chorea, contact lens intolerance, steeping of corneal curvature, pulmonary thromboembolism, carbohydrate intolerance.
|
|
Drug Interactions
Substrate of CYP1A2, 2A6, 2B6, 2C8/9, 2C19, 2D6, 2E1, 3A4; inhibits CYP1A2; induces CYP3A4. Effect decrease by rifampin, nelfinavir, ritonavir and anticonvulsants, folic acid.
|
|
Food Interaction
Black cohosh, dong quai, red clover, saw palmetto, ginseng, St. John's wort.
|
|
Lab Interference
Reduced response to metyrapone test. May interfere with thyroid function and glucose tolerance tests.
|
|
Action
Description: Estrone is a naturally occurring steroidal oestrogen.
|
|
Storage
Store below 25°C.
|
Sign Out
